Jamie Cesanek

A multicenter study found that using lenvatinib for initial treatment helped to increase survival in patients with stage B2 hepatocellular carcinoma.

The phase 1b/2 EQUATE study demonstrated high clinical responses to itolizumab for patients with acute graft vs host disease.

Patients with chronic lymphocytic leukemia experienced improved quality of life after being treated with continuous ibrutinib and rituximab, as well as frontline fludarabine, cyclophosphamide, and rituximab.

A population of patients with relapsed/refractory multiple myeloma appeared to benefit from treatment with selinexor plus daratumumab, bortezomib, and dexamethasone

Overall survival in patients with de novo metastatic castration-sensitive prostate cancer improves with addition of prednisone and abiraterone to androgen-deprivation therapy plus docetaxel.

Ciltacabtagene autoleucel may provide patients with myeloma who have developed progressive disease a more long-term treatment option.

Findings from a phase 1/2 study indicated that patients with relapsed/refractory multiple myeloma who were treated with iberdomide plus dexamethasone and daratumumab/bortezomib or carfilzombib experienced promising efficacy and tolerable safety.

Patients with multiple myeloma with standard or high-risk cytogenic abnormalities who were treated with carfilzomib, lenalidomide, and dexamethasone plus autologous stem cell transplant experienced promising responses.

Further investigation will determine if initial results regarding the use of anakinra as prophylaxis for orvacabtagene autoleucel in multiple myeloma is efficacious enough for use in the real-world setting.

Almost all patients with nonmetastatic castration-resistant prostate cancer treated on the phase 3 ARAMIS trial were able to receive the full planned dose of darolutamide for their disease.

Patients with non-small cell lung cancer receiving alectinib did not have better results than patients receiving crizotinib.

Data presented at the 2021 ASCO Annual Meeting from the phase 3 PACIFIC trial show long-term survival benefit for patients with unresectable stage III non–small cell lung cancer treated with durvalumab following chemoradiotherapy.

A new Chemotherapy Education Policy at an NCCN-designated oncology center was received well by nursing and pharmacy staff, yet failed to meet its goals of better-informing patients about their therapy prior to their first dose.